It has been approved for those who have not responded to other treatments first though. One more for Amgen. BD
The Food and Drug Administration approved on Friday Nplate, a drug produced by Amgen Inc. which stimulates bone marrow to produce blood platelets for patients suffering from chronic immune thrombocytopenic purpura (ITP). The condition affects more than 140,000 people and involves immediate bruising and bleeding after minor injuries. Also, it is known to cause nose bleeding and bleeding gums and its complications include subarachnoid and intracerebral hemorrhage.
Amgen Inc. is a well known international biotechnology company, with its main office situated in Thousand Oaks, California. It produces a wide variety of drugs, including Epogen, Enbrel, Neulasta, Neupogen, Aranesp.